All Blogs

Jun 19, 2024

Duchenne muscular dystrophy (DMD) is a severe genetic disorder primarily affecting young boys between the ages of two and three. As per Delveinsight’s estimates, there were approximately 16K DMD patients in 2023 in the United States, with ˜75% of the patients below the age of 15. This condition leads to progressive...

Jun 26, 2024

Asthma is a major noncommunicable disease that impacts both children and adults, and it is the most prevalent chronic condition among children. In 2019, ~262 million individuals were impacted by asthma, resulting in 455K deaths all over the world. More than 27 million individuals in the United States suffer from...

Jun 18, 2024

Takeda Reveals Phase III Results for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes Takeda revealed topline results from its SKYLINE and SKYWAY studies. SKYLINE (TAK-935-3001) was a multicenter, randomized, double-blind Phase III trial assessing soticlestat (TAK-935) plus standard care against plac...

Jun 17, 2024

Merck’s investment of $11.5 billion in acquiring Acceleron Pharma is expected to yield significant returns with the FDA’s approval of WINREVAIR (sotatercept), a pivotal component of the acquisition, for the treatment of pulmonary arterial hypertension. An estimated prevalence of pulmonary hypertension at the pop...

Jun 14, 2024

Bristol Myers Squibb’s PD-1 inhibitor, OPDIVO, has deep roots in Japan. In July 2014, MHLW approved OPDIVO to treat melanoma, marking it the first approved PD-1 inhibitor globally. About two years later, KEYTRUDA gained approval in Japan for the same indications (melanoma and NSCLC). This set the stage for fierce c...

Jun 13, 2024

Asensus Surgical Agreed to be Acquired by Karl Storz  On June 07, 2024, Asensus Surgical announced that it had entered a deal in which Karl Storz would acquire the company for 35¢ per share in cash. Karl Storz Endoscopy-America, a wholly-owned subsidiary of Germany-based Karl Storz, had agreed to acquire...

Jun 12, 2024

In contemporary healthcare, technological progress has profoundly reshaped how patients are treated. One such innovation that has revolutionized healthcare delivery is the development of infusion therapy devices. These devices have become indispensable tools in administering fluids, medications, and nutrients direc...

Jun 11, 2024

Moderna Reports Successful Phase III Trials for Dual Influenza and COVID-19 Vaccine Moderna, Inc. has reported that its Phase III trial for mRNA-1083, an experimental combination vaccine targeting both influenza and COVID-19, achieved its main objectives by generating a stronger immune response than the approved...

Jun 10, 2024

Myelofibrosis is a rare disease with a high unmet need, with no disease-modifying treatments. Before 2011, treatment options for myelofibrosis were limited to either allogeneic transplant or palliation. Currently, Janus kinase (JAK) inhibitors have become the mainstay of pharmacologic therapy for myelofibrosis pati...

Jun 07, 2024

Wet AMD, comprising around 10% of the total AMD population, is primarily the target of pharmaceutical companies, representing a market worth billions of dollars. With only two FDA-approved treatments, dry AMD presents a substantial market potential, encompassing approximately 90% of all AMD patients. Key players...